FarzanaPerwadMD

Pediatric Nephrology • San Francisco, CA

Pediatric Hypertension Nephrology

Assistant Professor, Pediatrics, UCSF School of Medicine

Join to view full profile

Dr. Perwad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Perwad's full profile

Already have an account?

Office
400 Parnassus Ave
Fl 2
San Francisco, CA 94143
Phone+1 415-353-2813

Fax+1 415-353-2334

Education & Training

University of California (San Francisco)Fellowship, Pediatric Nephrology, 2002 - 2006
Nicklaus Children's HospitalResidency, Pediatrics, 1998 - 2001
Kasturba Medical College ManipalClass of 1996

Certifications & Licensure

CA State Medical License 2001 - 2025
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Nephrology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Publications & Presentations

PubMed

7 citations
Association of Genetically Predicted Fibroblast Growth Factor-23 with Heart Failure: A Mendelian Randomization Study.
Elvis Akwo, Mindy M Pike, Lale A Ertuglu, Nicholas Vartanian, Eric Farber-Eger
Clinical Journal of the American Society of Nephrology. 2022-08-01
183 citations
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial
Erik A. Imel, Francis H. Glorieux, Michael P. Whyte, Craig F Munns, Leanne Ward
Lancet. 2019-06-15
187 citations
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: W...
Karl L. Insogna, Karine Briot, Erik A. Imel, Peter Kamenický, Mary D. Ruppe
Journal of Bone and Mineral Research. 2018-08-01

Journal Articles

A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults with X‐Linked Hypophosphatemia: W...
Thomas Weber, Mary D Ruppe, Anthony A Portale, Erik A Imel, Thomas O Carpenter, Karl L Insogna, Farzana Perwad, Pisit Pitukcheewanont, Journal of Bone and Mineral Research